JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB153987

Anti-LCLAT1 antibody

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Polyclonal LCLAT1 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human LCLAT1 aa 150 to C-terminus.

View Alternative Names

AGPAT8, ALCAT1, LYCAT, UNQ1849/PRO3579, LCLAT1, Lysocardiolipin acyltransferase 1, 1-acylglycerol-3-phosphate O-acyltransferase 8, Acyl-CoA:lysocardiolipin acyltransferase 1, 1-AGP acyltransferase 8, 1-AGPAT 8

1 Images
Western blot - Anti-LCLAT1 antibody (AB153987)
  • WB

Unknown

Western blot - Anti-LCLAT1 antibody (AB153987)

10% SDS PAGE

All lanes:

Western blot - Anti-LCLAT1 antibody (ab153987) at 1/500 dilution

Lane 1:

HeLa whole cell lysate at 20 µg

Lane 2:

HeLa membrane lysate at 20 µg

Predicted band size: 49 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Recombinant Fragment Protein within Human LCLAT1 aa 150 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

Q6UWP7

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: 78.99% PBS, 20% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Lysocardiolipin acyltransferase 1 (LCLAT1) also known as monolysocardiolipin acyltransferase (MLCL AT-1) is an enzyme with a mass of approximately 58 kDa. LCLAT1 resides primarily in the mitochondria and plays a significant role in phospholipid metabolism by catalyzing the reacylation of monolysocardiolipin (MLCL) to cardiolipin (CL). This function is critical for maintaining mitochondrial membrane structure and function. Expression of LCLAT1 occurs in various tissues with notable presence in heart and skeletal muscle where high energy demand correlates with mitochondrial activity.
Biological function summary

LCLAT1 functions within the lipid remodeling pathway specific to the mitochondria and is an important player in the maintenance of mitochondrial function and energy metabolism. This enzyme acts independently not as part of a larger protein complex. LCLAT1 ensures the proper composition of cardiolipin which is essential for the optimal performance of respiratory chain complexes and cellular energy homeostasis.

Pathways

The enzyme LCLAT1 plays a vital role in lipid metabolism particularly the remodeling pathway of cardiolipin in mitochondria. This pathway is vital for the functionality of the electron transport chain an important element in cellular respiration. LCLAT1 interconnects with Tafazzin (TAZ) another enzyme critical in cardiolipin biosynthesis and remodeling highlighting its participation in maintaining mitochondrial health and efficient aerobic energy supply.

Alterations in LCLAT1 function have connections to mitochondrial diseases due to its role in cardiolipin remodeling. Disruptions in its activity may relate to Barth syndrome a genetic disorder linked to defects in cardiolipin metabolism. LCLAT1's association with Tafazzin (TAZ) further implicates it in the disorder as both proteins are essential for proper cardiolipin function and mitochondrial integrity.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Exhibits acyl-CoA : lysocardiolipin acyltransferase (ALCAT) activity; catalyzes the reacylation of lyso-cardiolipin to cardiolipin (CL), a key step in CL remodeling (By similarity). Recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors (By similarity). Also exhibits 1-acyl-sn-glycerol-3-phosphate acyltransferase activity (AGPAT) activity; converts 1-acyl-sn-glycerol-3- phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3- phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone (PubMed : 16620771). Possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities (PubMed : 19075029). Required for establishment of the hematopoietic and endothelial lineages (By similarity).
See full target information LCLAT1
style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

European journal of medical research 28:209 PubMed37393390

2023

Abnormal expression of fission and fusion genes and the morphology of mitochondria in eutopic and ectopic endometrium.

Applications

Unspecified application

Species

Unspecified reactive species

Chaoshuang Ye,Pei Chen,Bingning Xu,Yang Jin,Yongchao Pan,Tianyu Wu,Yongjiang Du,Jingxia Mao,Ruijin Wu

Free radical biology & medicine 158:171-180 PubMed32726688

2020

Aerobic exercise alleviates oxidative stress-induced apoptosis in kidneys of myocardial infarction mice by inhibiting ALCAT1 and activating FNDC5/Irisin signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Fangnan Wu,Zhuo Li,Mengxin Cai,Yue Xi,Zujie Xu,Zezhou Zhang,Hangzhuo Li,Wanyu Zhu,Zhenjun Tian
View all publications
style
left-column
style
left-column
style
right-column

Alternative Products

Primary Antibodies

AB122197

Anti-LCLAT1 antibody

Immunocytochemistry - Anti-LCLAT1 antibody (AB122197)

  • 0
  • 0

Complementary Products

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB214034

Anti-LPCAT1 antibody [EPR19882]

RabMAb|Recombinant

Flow Cytometry (Intracellular) - Anti-LPCAT1 antibody [EPR19882] (AB214034)

  • 0
  • 0
Primary Antibodies

AB168479

Anti-PTPMT1 antibody

Western blot - Anti-PTPMT1 antibody (AB168479)

  • 0
  • 0
Primary Antibodies

AB92547

Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker

BOND RX™ Validated|KO Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size|Advanced Validation

Multiplex immunohistochemistry - Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (AB92547)

  • 5
  • 92

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com